Medical News

RSS

MedClean 2011 total revenue increases 91% to $1,717,721

MedClean Technologies, Inc. today announced financial results for the 12-month period ended December 31, 2011.

16 May 2012

First study to compare complication rates after RAPN and LPN

Robot-assisted surgery has replaced another minimally invasive operation as the main procedure to treat kidney cancer while sparing part of the diseased organ, and with comparable results, according to a new research study by Henry Ford Hospital urologists.

16 May 2012

Two specific gene variants speed progression of Parkinson's disease

UCLA researchers may have found a key to determining which Parkinson's disease patients will experience a more rapid decline in motor function, sparking hopes for the development of new therapies and helping identify those who could benefit most from early intervention.

16 May 2012

Positive results from Boston Scientific's Lotus Aortic Valve System trial

Boston Scientific Corporation announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus Aortic Valve System in patients with severe aortic valve disease.

16 May 2012

Researchers eager to teach Swedes about best brushing technique

Almost all Swedes brush their teeth, yet only one in ten does it in a way that effectively prevents tooth decay. Now researchers at the Sahlgrenska Academy, University of Gothenburg, are eager to teach Swedes how to brush their teeth more effectively.

16 May 2012

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.

16 May 2012

AUXILIO first quarter net revenue increases 40% to $6.5 million

AUXILIO, Inc., the nation's pioneer and leading Managed Print Services (MPS) company for health care, announced its financial results for the quarter ended March 31, 2012.

16 May 2012

Exendin-4 drug effectively suppresses craving for food

A drug made from the saliva of the Gila monster lizard is effective in reducing the craving for food. Researchers at the Sahlgrenska Academy, University of Gothenburg, have tested the drug on rats, who after treatment ceased their cravings for both food and chocolate.

16 May 2012

AxioMed’s Freedom Cervical Disc receives CE Mark approval

AxioMed Spine Corporation announces the receipt of CE Mark approval for its Freedom Cervical Disc, an elastomeric total spinal disc replacement device.

16 May 2012

Rice University students create mechanism to regulate IV fluids for children

Instead of building a better mousetrap, a team of Rice University freshmen took a mousetrap and built a better way to treat dehydration among children in the developing world.

16 May 2012

Emdeon first quarter revenue increases 5.4% to $286.0 million

Emdeon Inc., a leading provider of healthcare revenue and payment cycle management and clinical information exchange solutions, today announced financial results for the first quarter ended March 31, 2012.

16 May 2012

Mass. Eye and Ear announces recipients of 2012 Curing Kids Fund grants

The Mass. Eye and Ear Curing Kids fund has awarded grants for research projects that aim to help the brain locate sound, identify genes that cause congenital blindness, cure deafness through hair cell regeneration, and improve treatment for childhood eye cancer.

16 May 2012

Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.

16 May 2012

Link between dietary supplements and increased risk of cancer

Beta-carotene, selenium and folic acid - taken up to three times their recommended daily allowance, these supplements are probably harmless. But taken at much higher levels as some supplement manufacturers suggest, these three supplements have now been proven to increase the risk of developing a host of cancers.

16 May 2012

IEHIE, SynerMed form partnership

SynerMed, Inc. announced today that it has formed a partnership with IEHIE that will link patient health information to medical providers across California.

16 May 2012

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.

16 May 2012

Coromega introduces emulsified form of omega-3s

Premier supplements maker Coromega today announced a delicious new way to help Americans reach healthy omega-3 levels with the launch of Coromega Big Squeeze, an emulsified form of omega-3s delivered in an easy-to-use, family-size pouch with superior absorption to that of traditional fish oil capsules.

16 May 2012

BiO2 Medical receives CE Mark approval for Angel Catheter to prevent PE

BiO2 Medical, Inc. a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, announced today that it has received CE Mark approval for the Angel Catheter, a Nitinol Inferior Vena Cava (IVC) filter, permanently attached to a central venous catheter (CVC) for the use of preventing Pulmonary Embolism (PE) in critically ill patients.

16 May 2012

PGI first quarter net sales increase to $295.2 million

Polymer Group, Inc. (PGI) reported results of operations for the first quarter ended March 31, 2012.

16 May 2012

Novelos completes I-131-CLR1404 Phase 1b trial on advanced solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the first cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.

16 May 2012